ePharmaSolutions' ReferralPlus Increases Match Rate For Clinical Trial Volunteers By More than 66%
ePharmaSolutions, a provider of eClinical solutions, announced positive results of initial pilot studies for its patient matching and triaging solution, ReferralPlus.
ePharmaSolutions, a provider of eClinical solutions, announced positive results of initial pilot studies for its patient matching and triaging solution, ReferralPlus™. ReferralPlus™ was designed by ePharmaSolutions as a tool to match patients who disqualify for one study with others they might qualify for using a geo-therapeutic matching algorithm with other studies listed on their technology.
In 2012, ePharmaSolutions organized more than 30 major pharmaceutical companies and CROs to participate in the pilots to determine if they could help increase enrollment rates by triaging/matching patients who disqualified from one clinical trial to trials listed by other participating sponsors. The pilots started at the end of 2013 with the early results showing a significant improvement in cross-study matching which will offer significant economic advantages to pharmaceutical companies recruiting patients while providing patients with more opportunities to find for the right study.
The pilot data came from three pharmaceutical companies who listed their studies on the CenterWatch™ web listing service and used the ReferralPlus™ screening and matching solution. None of the pilot studies included an advertising outreach budget.
The results are summarized below:
- 33% of the total patients who screened for one study were eligible for and referred to a study site
- 18% of patients who disqualified from the first study, pre-qualified and were referred to another study
- 50% of patients who disqualified for any of the studies listed, registered to be contacted about future studies
Read the full release here.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
